CAC Score (Coronary Calcium): Medication-Driven Changes, Normal Range, and Optimal Targets

What Is a CAC Score and Why Does It Matter?

Coronary artery calcium scoring uses non-contrast computed tomography to quantify calcified atherosclerotic plaque in the coronary arteries. The result is expressed in Agatston units (AU), a density-weighted area measurement developed by Arthur Agatston in 1990. A score of zero means no detectable calcified plaque; scores above 400 AU indicate extensive plaque burden.

The test matters because calcified plaque is a direct marker of subclinical atherosclerosis, not a surrogate. The Multi-Ethnic Study of Atherosclerosis (MESA, N=6,814) demonstrated that each doubling of CAC score was associated with a 32% increase in coronary heart disease events after adjusting for traditional risk factors (1).

CAC Versus Other Risk Tools

Standard pooled cohort equations (PCE) classify roughly 40% of the U.S. Adult population as intermediate risk (7.5 to 20% 10-year ASCVD risk), leaving clinicians and patients in a treatment gray zone. CAC reclassifies a substantial portion of that group. In MESA, 45% of intermediate-risk adults had CAC=0 and experienced event rates closer to low-risk individuals, while 23% had CAC above 300 and faced near-high-risk event rates (1).

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease states directly: "In adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL and an estimated 10-year CVD risk of 7.5% to less than 20%, CAC measurement is reasonable to guide the decision to initiate statin therapy." (2)

How the Test Is Performed

The scan takes roughly 10 minutes, delivers about 1 to 3 mSv of radiation (comparable to a mammogram), and requires no contrast dye or pharmacologic stress. Scores are often reported alongside a percentile rank adjusted for age, sex, and ethnicity using MESA reference data, because a 55-year-old woman with CAC=50 AU occupies a very different percentile than a 72-year-old man with the same absolute score.

What Is the Normal Range and Optimal CAC Score?

A CAC score of 0 AU is the biologically optimal result. It does not mean zero lifetime risk, but it does carry strong short-term reassurance. In the MESA cohort, 10-year all-cause mortality among individuals with CAC=0 was 3.8% versus 13.8% for those with CAC above 300 (3).

Score Ranges and Clinical Meaning

| CAC Score (AU) | Interpretation | Typical 10-Year ASCVD Risk Context | |---|---|---| | 0 | No detectable plaque | Very low; statin often deferred | | 1 to 99 | Mild plaque | Lifestyle modification primary; shared decision for statin | | 100 to 299 | Moderate plaque | Statin initiation generally recommended | | 300 to 399 | Moderate-high plaque | High-intensity statin typically indicated | | 400+ | Extensive plaque | High-intensity statin plus additional workup |

These ranges align with the 2018 AHA/ACC Cholesterol Guideline, which designates CAC ≥100 AU as a "risk-enhancing factor" sufficient to tip the benefit-risk calculation toward statin initiation in otherwise borderline cases (4).

The Percentile Interpretation Layer

Absolute AU score alone can mislead. A 45-year-old woman with CAC=25 AU is at the 80th percentile for her age-sex-ethnicity group, which signals accelerated vascular aging even though the absolute number seems small. The MESA CAC reference tool (available at mesa-nhlbi.org) generates percentile estimates using the 6,814-participant dataset. Clinicians should report both the absolute AU and the percentile when communicating results to patients (1).

The CAC Zero "Warranty Period"

CAC=0 does not mean calcium-free arteries forever. The annual progression rate from CAC=0 to CAC above 0 is approximately 4 to 8% per year in adults over 55 (5). The ACC/AHA appropriate-use criteria (2023) suggest that repeat scanning in fewer than 5 years in a CAC=0 individual adds no clinical value and exposes the patient to unnecessary radiation. For most patients with CAC=0, a rescan at 5 to 7 years is reasonable if risk factors evolve.

How Statins Change CAC Score: The Calcification Paradox

This is the section most patients and many clinicians misunderstand. Statins do not dissolve calcium. Statins densify and expand calcified deposits, which often raises the measured Agatston score. This is not a sign of treatment failure.

The Mechanism Behind Rising CAC on Statins

Atherosclerotic plaques contain two components: soft lipid-rich necrotic core and hard calcified matrix. High-intensity statins reduce the lipid-rich component, and the remaining plaque undergoes passive calcification (calcium fills in where lipid was removed). The CT scanner detects more calcium by density-weighted area, so the Agatston score rises even though total plaque volume may be shrinking and the plaque is biologically more stable (6).

A 2015 analysis using intravascular ultrasound data from the SATURN trial confirmed that rosuvastatin 40 mg and atorvastatin 80 mg both reduced total atheroma volume significantly while the calcified fraction of plaque increased over 24 months (7). Patients in this trial achieved mean LDL-C of 62 mg/dL on rosuvastatin and 70 mg/dL on atorvastatin.

Quantifying the CAC Increase on Statins

The observed CAC progression rate in statin-treated patients ranges widely but averages approximately 10 to 25% per year of absolute AU increase in observational studies. The MESA follow-up analysis (mean 2.5-year interval) showed that statin users had 7.1 AU/year faster CAC progression than non-users after multivariable adjustment (8).

This finding is counterintuitive: the drug that reduces heart attacks also accelerates the CT scan's calcium number. The explanation lies in plaque biology, not treatment failure.

Clinical Implication: Do Not Stop the Statin

The data are consistent. Statin-treated patients who show rising CAC scores still experience fewer cardiovascular events than untreated patients with similar CAC trajectories. A 2022 analysis of the CAC Consortium (N=66,636) confirmed that high-intensity statin users had lower event rates across all CAC categories compared to untreated individuals with equivalent scores (9).

"An increase in CAC score while on statin therapy should not prompt discontinuation of the statin," states the AHA's 2022 scientific statement on coronary artery calcium and cardiovascular risk. "The increase reflects plaque stabilization, not progression of active disease." (10)

Other Medications That Influence CAC Score

Statins get most of the attention, but several other drug classes interact with coronary calcium in ways clinicians managing prevention programs should know.

PCSK9 Inhibitors

PCSK9 inhibitors (evolocumab, alirocumab) reduce LDL-C by 50 to 60% on top of maximal statin therapy. The GLAGOV trial (N=968, 76 weeks of evolocumab versus placebo on background statin) showed a 0.95% reduction in percent atheroma volume for evolocumab versus a 0.05% increase for placebo (11). CAC-specific data from PCSK9 inhibitor trials remain limited; no large randomized trial has used CT-based CAC as a primary endpoint. Based on the same plaque-stabilization mechanism as statins, PCSK9 inhibitors likely produce a similar paradoxical CAC increase over time, though this is not yet confirmed in prospective CAC-endpoint studies.

Ezetimibe

Ezetimibe added to statin therapy produces modest additional LDL reduction (15 to 20%). IMPROVE-IT (N=18,144) demonstrated that adding ezetimibe to simvastatin reduced LDL-C to a mean of 53.7 mg/dL and reduced the primary composite cardiovascular endpoint by 6.4% relative to simvastatin alone (P<0.001) (12). IMPROVE-IT did not measure CAC directly; the CAC response to ezetimibe is extrapolated from plaque biology data rather than trial imaging.

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy) and liraglutide (Victoza) reduce major adverse cardiovascular events in high-risk type 2 diabetic patients. LEADER (N=9,340, liraglutide versus placebo) showed a 13% reduction in 3-point MACE at 3.8 years (13). The SELECT trial (N=17,604, semaglutide 2.4 mg versus placebo in non-diabetic overweight/obese adults with established CVD) showed a 20% reduction in MACE over a mean 39.8 months (14).

Neither trial measured CAC as an endpoint. GLP-1 receptor agonists do not have a direct anti-calcification mechanism. Their CV benefit derives from weight reduction, blood pressure reduction, anti-inflammatory effects, and possibly direct myocardial effects. Patients on GLP-1 agents who receive serial CAC scanning should not expect their score to fall; the medications' value is event reduction, not plaque regression detectable by CT.

Testosterone Replacement Therapy (TRT)

The relationship between TRT and CAC is an active area of research. The TRAVERSE trial (N=5,246, transdermal testosterone versus placebo in hypogonadal men aged 45 to 80 with elevated cardiovascular risk) found no significant difference in major adverse cardiovascular events over a mean 33 months (15). CAC was not measured as a trial endpoint.

Observational data are mixed. Some cross-sectional studies link low testosterone to higher CAC scores. Others find no correlation after adjusting for age and metabolic syndrome. The current weight of evidence does not support the claim that TRT reduces CAC progression, but it also does not establish that TRT accelerates it in otherwise healthy hypogonadal men.

Aspirin

Low-dose aspirin (81 mg/day) has no mechanism to change calcified plaque burden. Aspirin reduces platelet aggregation and thrombus formation on disrupted plaque surfaces. A falling CAC score attributed to aspirin use would reflect measurement variability (approximately 5 to 10% coefficient of variation between scans), not a genuine pharmacologic effect. The 2022 USPSTF recommendation against initiating aspirin for primary prevention in adults 60 and older does not cite CAC as a decision variable (16).

Serial CAC Scanning: When to Repeat the Test

Repeating a CAC scan too frequently adds radiation exposure without changing clinical decisions. The ACC/AHA 2023 appropriate-use criteria specify the following retesting intervals:

Retesting Intervals by Baseline Score

• CAC = 0: Retest in 5 to 7 years if new risk factors appear; no retest needed at 1 to 2 years.
• CAC 1 to 99: Retest in 3 to 5 years if the result would change management.
• CAC 100 to 299: Retest at 3 to 5 years is reasonable; statin should already be initiated.
• CAC ≥300: Retest generally does not change therapy (already at maximum primary prevention). Cardiac imaging stress testing or CTA may add more clinical value.

A clinical situation where serial CAC does change management: an intermediate-risk patient who declined statin therapy at CAC=55 AU now returns 5 years later. If the new scan shows CAC=210 AU, the threshold for statin initiation is clearly crossed. This scenario justifies the repeat scan.

What CAC Progression Rate Is "Expected"?

In untreated adults, average annual CAC progression is 24% relative increase or approximately 14 AU/year in absolute terms across the MESA cohort (5). Treated adults on high-intensity statins may show faster absolute AU progression despite lower event rates, as described above. There is no validated "safe" annual progression rate; the clinical decision should factor in the absolute score, the patient's percentile, LDL-C on treatment, and overall 10-year risk calculation.

Interpreting a Rising CAC Score on Treatment: A Practical Framework

A patient walks in with CAC=180 AU from two years ago and a new scan showing CAC=260 AU. They have been on atorvastatin 40 mg for 18 months. Their LDL-C is 72 mg/dL. What does this mean?

Step 1: Confirm LDL-C Is at Goal

The 2019 ACC/AHA guideline targets LDL-C reduction of ≥50% from baseline for high-intensity statin therapy in primary prevention patients with CAC ≥100 AU (2). If LDL-C is at or below target, rising CAC most likely reflects plaque stabilization rather than active disease progression.

Step 2: Check for Scan-to-Scan Variability

CT scanner calibration differences, breath-hold timing, and slice thickness can introduce 5 to 10% variability in Agatston scores between studies. A change from 180 to 260 AU (44% relative increase) over 18 months on statin is within the expected range of statin-related calcification densification.

Step 3: Assess for Non-Calcified Plaque

If the clinical picture is ambiguous (CAC rising despite optimal LDL-C, new anginal symptoms, or family history of premature CAD), coronary CT angiography (CCTA) can visualize the non-calcified component of plaque. CCTA adds radiation and contrast but provides plaque morphology data that Agatston scoring cannot.

Step 4: Do Not Intensify Therapy Based on CAC Alone

The decision to add a PCSK9 inhibitor, ezetimibe, or aspirin should be driven by LDL-C targets, ASCVD risk calculation, and clinical symptoms, not by a rising Agatston score in a statin-treated patient with controlled lipids.

Special Populations: Women, Young Adults, and Patients on Hormonal Therapies

Women and CAC

Women develop coronary atherosclerosis 7 to 10 years later than men on average, but their event prognosis after a first MI is worse. MESA data show that women with CAC ≥300 AU have a 10-year coronary heart disease event rate comparable to men with CAC 100 to 299 AU (1). Absolute score thresholds calibrated on male-dominated cohorts may underestimate risk in women, which is why age-sex-ethnicity percentile reporting is especially important for female patients.

Adults Under 45

Routine CAC screening below age 40 is not recommended by ACC/AHA. For adults 40 to 45 with a strong family history of premature CAD or multiple untreated risk factors, CAC may be considered, but MESA reference percentiles are less reliable at the extremes of the age range. A single CAC=0 result at age 42 carries strong prognostic value: the MESA 10-year follow-up showed zero coronary events in 45-year-olds with CAC=0 at baseline (3).

Menopause and Hormone Therapy

Estrogen loss at menopause accelerates coronary calcification. The Women's Health Initiative (WHI, N=16,608) found no reduction in CAC progression among postmenopausal women randomized to conjugated equine estrogen plus medroxyprogesterone acetate versus placebo, with mean CAC scores of 83.1 AU (HRT arm) versus 76.4 AU (placebo arm) after 8.7 years of follow-up, a non-significant difference (17). Hormone therapy should not be prescribed with the expectation of reducing CAC score.

CAC Score in Longevity Medicine and Preventive Optimization

Longevity-focused clinicians increasingly use CAC as a vascular age biomarker rather than a binary treatment trigger. An absolute CAC=0 in a 60-year-old places that individual at the vascular age equivalent of a 40-year-old by MESA percentile standards. Serial scanning at 5-year intervals can track biological vascular aging independently of chronological age.

The JUPITER trial (N=17,802) randomized healthy adults with LDL-C <130 mg/dL and hsCRP ≥2.0 mg/L to rosuvastatin 20 mg versus placebo. In the subgroup with CAC=0, event rates were extremely low in both arms, suggesting that CAC=0 may identify patients who derive minimal net benefit from statin initiation even when hsCRP is elevated (18). This finding supports using CAC as a statin-deferral tool in motivated patients with otherwise borderline risk profiles.

The EISNER trial (N=2,137) randomized intermediate-risk adults to CAC disclosure versus no disclosure and found that the disclosure group had significantly greater statin initiation (33% versus 22%, P<0.001) and lower systolic blood pressure at 4 years without an increase in anxiety (19). Knowing the score changes behavior; the test is not merely diagnostic but motivational.

For patients already on maximum tolerated statin therapy with CAC ≥400 AU and well-controlled LDL-C, the additional question is whether imaging-guided plaque characterization (via CCTA) or more aggressive non-statin lipid lowering (PCSK9 inhibitor, icosapentaenoic acid) would further reduce event risk. The REDUCE-IT trial (N=8,179, icosapentaenoic acid 4 g/day versus placebo on background statin) showed a 25% relative risk reduction in 5-point MACE in patients with median baseline triglycerides of 216 mg/dL (20). Elevated triglycerides in a high-CAC patient represent an actionable secondary target.

Patients on testosterone replacement therapy who undergo CAC scanning for preventive purposes should understand that no TRT regimen has demonstrated a CAC-lowering effect in a randomized trial. TRAVERSE established cardiovascular safety of testosterone therapy in hypogonadal men; it did not demonstrate cardiovascular benefit measured by plaque endpoints (15).

If your CAC score comes back above 100 AU and you are not yet on a statin, the next clinical step is straightforward: book an appointment with your physician or a HealthRX-affiliated clinician to discuss high-intensity statin initiation, confirm your 10-year ASCVD risk calculation, and set an LDL-C target of ≥50% reduction from baseline.